phenothiazin-1-one | 54819-17-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: phenothiazin-1-one
• 英文别名: Phenothiazine-1-one
• CAS: 54819-17-9
• 化学式: C₁₂H₇NOS
• 分子量: 213.26
• InChiKey: CPQFLZCJWDFFEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  phenothiazin-1-one 生成 7H-7,15b-etheno-phenothiazino[3,4-b]phenothiazine-6,8-dione
  参考文献：
  名称：

  SILBERG I. A.; BARTHA M., TETRAHEDRON LETT. , 1974, NO 43, 3801-3804

  摘要：

  DOI：
• 作为产物：
  描述：

  1-羟基-10H-吩噻嗪 在 lead dioxide 作用下， 生成 phenothiazin-1-one
  参考文献：
  名称：

  1H - phenothiazin - 1 - ones, a new class of heterocyclic -quinoneimines

  摘要：

  DOI：

  10.1016/s0040-4039(01)92013-1

文献信息

• Pyrroloquinoline and pyrrolophenothiazine carboxamides and related
  申请人：Pfizer Inc.

  公开号：US05624929A1

  公开（公告）日：1997-04-29

  Compounds of the formula ##STR1## wherein the broken line represents an optional double bond; X is O, S, CH.sub.2 or CH.sub.2 CH.sub.2 ; R.sup.1 is selected from the group consisting of hydrogen, halogen, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkanoyl, C.sub.1 -C.sub.6 alkyl, and C.sub.1 -C.sub.6 alkyl substituted with 1, 2 or 3 halogen atoms; R.sup.2 is selected from the group consisting of phenyl, substituted phenyl, heterocyclic groups, and substituted heterocyclic groups, said substituted phenyl and substituted heterocyclic groups being substituted with 1 or 2 substituents independently selected from the group consisting of C.sub.1 -C.sub.6 alkyl, trifuluoromethyl, and halogen; R.sup.3 and R.sup.4 are independently selected from the group consisting of hydrogen, halogen, C.sub.1 -C.sub.6 alkyl, or trifluoromethyl, or R.sup.3 and R.sup.4, taken together with the carbon atoms to which they are attached, form a six-membered carbocyclic aromatic ring, said aromatic ring being optionally substituted with one or two substituents selected from the group consisting of halogen, C.sub.1 -C.sub.6 alkyl, and C.sub.1 -C.sub.6 alkyl substituted with 1, 2 or 3 halogen atoms; and the pharmaceutically acceptable salts thereof. The compounds are useful in treating inflammation or other prostaglandin or leukotriene mediated diseases.

  公式为##STR1##的化合物，其中断裂的线代表可选的双键；X为O、S、CH.sub.2或CH.sub.2 CH.sub.2；R.sup.1选自氢、卤素、C.sub.1-C.sub.6烷氧基、C.sub.1-C.sub.6烷酰基、C.sub.1-C.sub.6烷基和1、2或3个卤素原子取代的C.sub.1-C.sub.6烷基；R.sup.2选自苯基、取代的苯基、杂环基和取代的杂环基，所述取代的苯基和取代的杂环基被1或2个取自C.sub.1-C.sub.6烷基、三氟甲基和卤素的取代基独立取代；R.sup.3和R.sup.4独立地选自氢、卤素、C.sub.1-C.sub.6烷基或三氟甲基，或R.sup.3和R.sup.4与它们附着的碳原子一起形成一个六元环的碳环芳基，所述芳基可以选择地被1或2个取自卤素、C.sub.1-C.sub.6烷基和1、2或3个卤素原子取代的取代基取代；以及其药学上可接受的盐。这些化合物用于治疗炎症或其他前列腺素或白三烯介导的疾病。
• Azolidinediones useful for the treatment of diabetes, dyslipidemia and
  申请人：Dr. Reddy's Research Foundation

  公开号：US06011031A1

  公开（公告）日：2000-01-04

  Novel antidiabetic compounds, their tautomeric forms, their derivatives, their analogues, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them; methods for preparing the antidiabetic compounds and their uses.

  小说抗糖尿病化合物，它们的互变异构体，它们的衍生物，它们的类似物，它们的立体异构体，它们的多晶型，它们的药学上可接受的盐，它们的药学上可接受的溶剂和含有它们的药学上可接受的组合物；制备抗糖尿病化合物的方法及其用途。
• AZOLIDINEDIONES USEFUL FOR THE TREATMENT OF DIABETES, DYSLIPIDEMIA AND HYPERTENSION
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：EP0977753A1

  公开（公告）日：2000-02-09
• US6011031A
  申请人：——

  公开号：US6011031A

  公开（公告）日：2000-01-04
• US6159966A
  申请人：——

  公开号：US6159966A

  公开（公告）日：2000-12-12